Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert tumor microenvironment and confers resistance to immunotherapy
J. Yan, Y. Chen, A. J. Patel, S. Warda, B. G. Nixon, E. W. P. Wong, M. A. Miranda-Roman, C. J. Lee, N. Yang, Y. Wang, J. Sher, E. Giff, F. Tang, E. Khurana, S. Singer, , P. Chi
This study shows that PRC2 inactivation in tumors creates an immune-desert microenvironment, leading to resistance to immunotherapy and suggests strategies to reverse this effect.
bioRxiv · May 27, 2022 · PreprintCancer Biology